All Trials & Treatments
Choose a cancer to learn more about...
A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors
Date: Last updated 4/13/2018
Regions: US; South; Investigational Site Number 8400006, Nashville, TN 37203; Investigational Site Number 8400003, Dallas, TX, 75230
Contact: For site information, send an email with site number to Contact-Us@sanofi.com
To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors, et al.
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
Date: Last updated 1/18/2018
Regions: Asia; Japan; St. Marianna University School of Medicine Hospital Recruiting, Kawasaki, 216-8511; National Cancer Center Hospital, Tokyo, 104-0045
Contact: Kawasaki: Takako Nakajima, MD, email@example.com, 044-977-8111; Tokyo: Toshio Shimizu, MD, firstname.lastname@example.org, +81 3-354-2511 ext 7003
This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in Japanese patients with advanced and metastatic solid tumor. The dose escalation will follow the widely used 3+3 design.
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
Date: Last updated 4/24/2018
Regions: Multi-region; US; Northeast and Mid-Atlantic; US; South; US; West Coast; US; Midwest; University of California San Diego Moores Cancer Center (Site 0004) La Jolla, CA 92093; UCLA Medical Center (Site 0003) Los Angeles, CA 90095; University of Chicago (Site 0002) Chicago, IL 60637; New York Presbyterian Hospital/Columbia University (Site 0001) New York, NY 10032; Mary Crowley Cancer Research Center (Site 0005) Dallas, TX 75246
Contact: Moores Cancer Center (Site 0004) Study Coordinator 858-822-6477; UCLA Medial Center (Site 0003) Study Coordinator 310-582-4048; University of Chicago (Site 0002) Study Coordinator 773-834-3096; New York Presbyterian Hospital/Columbia University (Site 0001) Study Coordinator 212-305-3997; Mary Crowley Cancer Research Center (Site 0005) Study Coordinator 214-658-1965
The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when administered via intratumoral (IT) injection as monotherapy and in combination with pembrolizumab (MK-3475) intravenous (IV) infusion.
The Study of SHR7390 in Combination With SHR-1210 in Patients With Advanced Solid Tumors
Date: Last updated 2/28/2018
Regions: Asia, China, The Cancer Center, Sun Yat-sen University Guangzhou, Guangdong, 510060
Contact: RuiHua Xu, MD, PhD 86-20-8734-3008 email@example.com or Yi Liu, PhD 86-21-6045-3192 ext 822 firstname.lastname@example.org.
This aim of study to assess the safety and tolerability of SHR7390 combined with SHR-1210 and to define Dose limiting toxicity（DLT）and the maximum tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors.
Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)
Date: Last updated 5/28/2018
Regions: Middle East; Israel; US; South; Texas Accelerated Research Therapeutics, LLC (START) (Site 0001), San Antonio, TX, 78229; Israel Rambam Medical Center (Site 0003) Haifa, Israel; Sheba Medical Center - Cancer Center ( Site 0002) Ramat-Gan, Israel
Contact: Site 0001 Study Coordinator: 210-593-5250; Site 0002 Study Coordinator: +97235307096; Site 0003 Study Coordinator: +97235307096; General: 1-888-577-8839, Trialsites@merck.com
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of MK-1308 when used in combination with pembrolizumab in participants with advanced solid tumors.
Special Combination of OBP-301 and Pembrolizumab
Date: Last updated 10/19/2017
Regions: Asia; Japan; National Cancer Center Hospital East; Kashiwa, Chiba
Contact: Takashi Kojima, Dr +81-4-7133-1111 ext 91266, OBPem_core@east.ncc.go.jp
This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.
Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Date: Last updated 1/4/2018
Regions: Multi-region; refer to contact details.
Contact: 1-888-669-6682, Novartis.email@example.com. Please refer to this study by its ClinicalTrials.gov identifier.
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Date: Last updated 6/12/2018
Contact: Use trial site search for specific contact details.
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
Date: Last updated 12/7/2017
Regions: Asia; China; Beijing - Capital Medical University Cancer Center/Beijing Shijitan Hospital Recruiting Beijing, Beijing, 100038
Contact: Jun Ren, MD, PhD 86-10-63926317, firstname.lastname@example.org
The purpose of this study is to compare the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody alone with anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy in advanced tumor patients.
Vaginal Cancer (HPV+)
E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers
Date: Last updated 6/8/2018
Regions: US; Northeast and Mid-Atlantic; National Institutes of Health Clinical Center, Bethesda, MD
Contact: Erin W Ferraro, R.N. (240) 760-6163, email@example.com
Researchers will take a person's blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the E7 protein unique to HPV cancers. The genetically changed cells, called E7 TCR cells, are then given back to the person to fight the cancer. Objective: To determine a safe dose of E7 TCR cells and whether these cells can help patients.
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (CheckMate358)
Date: Last updated 5/22/2018
Regions: Multi-region; Recruiting sites have contact information.
Contact: Please contact the sites directly: firstname.lastname@example.org; First line of the email MUST contain NCT# and Site #.
The purpose of this study to investigate the safety and effectiveness of Nivolumab, and Nivolumab combination therapy, to treat patients who have virus-associated tumors.
HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers, HESTIA
Date: Last updated 4/25/2018
Regions: US; South; Houston Methodist Hospital, Houston, TX
Contact: Carlos A. Ramos, MD 832-824-4817, email@example.com or Vicky Torrano 832-824-7821, firstname.lastname@example.org
The purpose of this study is to find the biggest dose of HPVSTs (special immune system cells) that is safe, to see how long they last in the body, to learn what the side effects are and to see if the HPVSTs will help people with HPV-associated cancers. (Click trial identifier to read more.)